Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

ACC 2024 | REDUCE AMI: Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction

Most clinical trials have shown benefits of beta blockers after acute myocardial infraction, including patients with extensive AMI, and these were carried out in the era before AMI was diagnosed with biomarkers and prior to treatment with coronary angioplasty, use of antithrombotic agents and high intensity statins, and angiotensin-aldosterone system inhibitors.

ACC 2024

The aim of this multicenter, randomized study was to assess the potential benefit of treatment with beta-blockers after AMI in patients with conserved left ventricular systolic function in the current era of percutaneous treatment and medical treatment. 

The primary outcome was a combination of all-cause death and non-fatal AMI. Secondary end point was a combination of all-cause death, AMI and hospitalization for cardiac failure. There was a safety end point including hospitalization for bradyarrhythmia, hypotension or syncope, hospitalization for asthma or COPD and hospitalization for stroke. 

5020 patients were randomized; 2508 to receiving beta-blockers (metoprolol or bisoprolol) and 2512 for conventional treatment. Mean age was 65 and most were men. Mean followup was 3.5 years. 35% of patients presented ST elevation AMI. 17% presented left main and three vessel disease, and most received percutaneous coronary intervention (PCI) (96%), while the remaining 4% underwent myocardial revascularization surgery (CABG).

Read also: ACC 2024 | SMART Trial: Self-Expanding or Balloon-Expandable TAVR in Patients with Small Aortic Annulus.

The primary outcome resulted 7.9% for the beta-blocker group vs. 8.3% for the conventional treatment group (HR 0.96; CI 95% 0.79-1.16; p=0.64). There were no differences in secondary and safety end points.

Conclusion 

Among patients with acute myocardial infarction undergoing early coronary angiography with conserved left ventricular ejection fraction (≥50%), treatment with beta-blockers at long term did not present lower risk of all cause death or new AMI or new myocardial infarction vs. no beta-blockers. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Beta-blockers after Myocardial Infarction and Preserved Ejection Fraction.

Reference: Troels Yndigegn et al ACC 2024.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...